Abstract Objective To identify risk factors for minimally invasive surfactant administration (MISA) failure in the treatment of preterm infants with respiratory distress syndrome (RDS) and the influence of MISA failure on neonatal outcome. Methods A retrospective analysis was performed for the clinical data of 148 preterm infants with a gestational age of ≤ 32 weeks and a clinical diagnosis of RDS, who were admitted to the neonatal intensive care unit of eight tertiary hospitals in Beijing, Tianjin and Hebei Province from July 1, 2017 to December 31, 2018 and were treated with MISA (bovine pulmonary surfactant, PS). According to whether MISA failure (defined as the need for mechanical ventilation within 72 hours after MISA) was observed, the infants were divided into two groups:MISA failure group (n=16) and MISA success (n=132). A logistic regression analysis was used to investigate the risk factors for MISA failure and its influence on neonatal outcome. Results The MISA failure rate was 10.8% (16/148). The logistic regression analysis showed that a high incidence rate of grade > II RDS before PS administration, low mean arterial pressure and high pulse pressure before administration, a low dose of initial PS administration, and long injection time and operation time were the risk factors for MISA failure (OR=5.983, 1.210, 1.183, 1.055, 1.036, and 1.058 respectively, P < 0.05). After the control for the above risk factors, the logistic regression analysis showed that the MISA failure group had a significantly higher incidence rate of bronchopulmonary dysplasia (BPD) (OR=8.537, P < 0.05). Conclusions A high grade of RDS, a low mean arterial pressure, and a high pulse pressure before administration are independent risk factors for MISA failure, and a low dose of initial PS administration, a long injection time, and a long operation time may increase the risk of MISA failure. MISA failure may increase the incidence rate of BPD in preterm infants.
LIU Hui-Qiang,TONG Xiao-Mei,HAN Tong-Yan et al. Risk factors for minimally invasive surfactant administration failure in preterm infants with respiratory distress syndrome[J]. CJCP, 2020, 22(3): 231-237.
LIU Hui-Qiang,TONG Xiao-Mei,HAN Tong-Yan et al. Risk factors for minimally invasive surfactant administration failure in preterm infants with respiratory distress syndrome[J]. CJCP, 2020, 22(3): 231-237.
Aguar M, Nuñez A, Cubells E, et al. Administration of surfactant using less invasive techniques as a part of a non-aggressive paradigm towards preterm infants[J]. Early Hum Dev, 2014, 90(Suppl 2):S57-S59.
[2]
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome-2016 update[J]. Neonatology, 2017, 111(2):107-125.
Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome-2019 update[J]. Neonatology, 2019, 115(4):432-450.
[5]
Verder H, Agertoft L, Albertsen P, et al. Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study[J]. Ugeskr Laeger, 1992, 154(31):2136-2139.
[6]
Kribs A, Pillekamp F, Hünseler C, et al. Early administration of surfactant in spontaneous breathing with nCPAP:feasibility and outcome in extremely premature infants (postmenstrual age ≤ 27 weeks)[J]. Paediatr Anaesth, 2007, 17(4):364-369.
[7]
Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimallyinvasive surfactant therapy in preterm infants on continuous positive airway pressure[J]. Arch Dis Child Fetal Neonatal Ed, 2013, 98(2):F122-F126.
[8]
Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV):an open-label, randomised, controlled trial[J]. Lancet, 2011, 378(9803):1627-1634.
[9]
Isayama T, Iwami H, McDonald S, et al. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants:a systematic review and meta-analysis[J]. JAMA, 2016, 316(6):611-624.
[10]
Janssen LC, Van Der Spil J, van Kaam AH, et al. Minimally invasive surfactant therapy failure:risk factors and outcome[J]. Arch Dis Child Fetal Neonatal Ed, 2019, 104(6):F636-F642.
Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia[J]. Semin Perinatol, 2013, 37(2):102-107.
[13]
Aguar M, Cernada M, Brugada M, et al. Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies[J]. Acta Paediatr, 2014, 103(6):e229-e233.
[14]
De Luca D, Minucci A, Gentile L, et al. Surfactant inadvertent loss using feeding catheters or endotracheal tubes[J]. Am J Perinatol, 2014, 31(3):209-212.
[15]
Niemarkt HJ, Kuypers E, Jellema R, et al. Effects of lessinvasive surfactant administration on oxygenation, pulmonary surfactant distribution, and lung compliance in spontaneously breathing preterm lambs[J]. Pediatr Res, 2014, 76(2):166-170.
[16]
Rigo V, Debauche C, Maton P, et al. Rigid catheters reduced duration of less invasive surfactant therapy procedures in manikins[J]. Acta Paediatr, 2017, 106(7):1091-1096.
[17]
Niemarkt HJ, Hütten MC, Kramer BW. Surfactant for respiratory distress syndrome:new ideas on a familiar drug with innovative applications[J]. Neonatology, 2017, 111(4):408-414.
[18]
Cogo PE, Facco M, Simonato M, et al. Dosing of porcine surfactant:effect on kinetics and gas exchange in respiratory distress syndrome[J]. Pediatrics, 2009, 124(5):e950-e957.
[19]
Manuck TA, Levy PT, Gyamfi-Bannerman C. Dosing of porcine surfactant:effect on kinetics and gas exchange in respiratory distress syndrome[J]. JAMA Pediatr, 2016, 170(5):e154577.
Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis[J]. J Clin Epidemiol, 1996, 49(12):1373-1379.
